JP2018523689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523689A5 JP2018523689A5 JP2018508757A JP2018508757A JP2018523689A5 JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5 JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- kit
- composition according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514760.6A GB201514760D0 (en) | 2015-08-19 | 2015-08-19 | Compounds and method of use |
| GB1514760.6 | 2015-08-19 | ||
| PCT/GB2016/052575 WO2017029517A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523689A JP2018523689A (ja) | 2018-08-23 |
| JP2018523689A5 true JP2018523689A5 (https=) | 2019-07-25 |
Family
ID=54258859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508757A Withdrawn JP2018523689A (ja) | 2015-08-19 | 2016-08-19 | ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10668077B2 (https=) |
| EP (1) | EP3337477B1 (https=) |
| JP (1) | JP2018523689A (https=) |
| KR (1) | KR20180064387A (https=) |
| CN (2) | CN113786409B (https=) |
| AU (1) | AU2016307885B2 (https=) |
| CA (1) | CA2995898A1 (https=) |
| DK (1) | DK3337477T3 (https=) |
| ES (1) | ES2939815T3 (https=) |
| FI (1) | FI3337477T3 (https=) |
| GB (1) | GB201514760D0 (https=) |
| HR (1) | HRP20230376T1 (https=) |
| HU (1) | HUE061615T2 (https=) |
| IL (1) | IL257499A (https=) |
| LT (1) | LT3337477T (https=) |
| MX (1) | MX2018001926A (https=) |
| PL (1) | PL3337477T3 (https=) |
| PT (1) | PT3337477T (https=) |
| RS (1) | RS64095B1 (https=) |
| SI (1) | SI3337477T1 (https=) |
| SM (1) | SMT202300063T1 (https=) |
| WO (1) | WO2017029517A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN01325A (https=) | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| SG11202102343QA (en) * | 2018-09-11 | 2021-04-29 | Curis Inc | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| JPWO2020059705A1 (ja) * | 2018-09-18 | 2021-08-30 | 株式会社ヤクルト本社 | キノリンカルボキサミド誘導体を用いるがん併用療法 |
| PT3930715T (pt) * | 2019-02-27 | 2024-08-02 | Astrazeneca Ab | Saracatinib para uso no tratamento de fibrose pulmonar idiopática |
| CN111904958B (zh) * | 2019-05-09 | 2022-09-13 | 浙江大学 | Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用 |
| GB201909468D0 (en) * | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| BE786081A (fr) * | 1971-07-13 | 1973-01-10 | Uniroyal Sa | Appareil et procede pour maintenir les tringles des bourrelets de pneu |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CN1250294A (zh) * | 1999-07-27 | 2000-04-12 | 邮电部武汉邮电科学研究院 | 以太网与同步数字体系或同步光网络融合的适配方法 |
| EA004872B1 (ru) | 1999-08-03 | 2004-08-26 | ЛИЛЛИ АЙКОС эЛ-эЛ-Си | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP2004502686A (ja) | 2000-06-30 | 2004-01-29 | スージェン・インコーポレーテッド | ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用 |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び／又は予防する方法 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| WO2006127587A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| RU2008141356A (ru) | 2006-04-26 | 2010-06-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k) |
| CN101511840A (zh) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| ES2365258T3 (es) | 2006-06-26 | 2011-09-27 | Ucb Pharma S.A. | Derivados de tiazol condensados como inhibidores de quinasa. |
| UA97483C2 (ru) * | 2006-08-08 | 2012-02-27 | Чугай Сейяку Кабушики Кайша | Производное пиримидина в качестве ингибитора pi3k и его применение |
| KR20090087027A (ko) | 2006-11-13 | 2009-08-14 | 일라이 릴리 앤드 캄파니 | 염증 질환 및 암의 치료를 위한 티에노피리미디논 |
| EP2120909A2 (en) | 2006-12-15 | 2009-11-25 | Ordway Research Institute | Treatments of therapy-resistant diseases comprising drug combinations |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| US20100063032A1 (en) | 2007-03-28 | 2010-03-11 | Debenham John S | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| CA2742550A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| IN2012DN01325A (https=) * | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN101849934B (zh) * | 2010-05-25 | 2011-11-09 | 苏州大学 | 一种磷脂酰肌醇-3-激酶抑制剂及其应用 |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| CN103702990B (zh) | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| RU2015118647A (ru) | 2012-11-20 | 2017-01-10 | Дженентек, Инк. | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr |
| NZ714283A (en) | 2013-05-10 | 2020-04-24 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| SG11201509842SA (en) * | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2015
- 2015-08-19 GB GBGB1514760.6A patent/GB201514760D0/en not_active Ceased
-
2016
- 2016-08-19 RS RS20230255A patent/RS64095B1/sr unknown
- 2016-08-19 MX MX2018001926A patent/MX2018001926A/es unknown
- 2016-08-19 DK DK16756763.5T patent/DK3337477T3/da active
- 2016-08-19 CN CN202111104917.2A patent/CN113786409B/zh active Active
- 2016-08-19 CA CA2995898A patent/CA2995898A1/en not_active Abandoned
- 2016-08-19 PT PT167567635T patent/PT3337477T/pt unknown
- 2016-08-19 PL PL16756763.5T patent/PL3337477T3/pl unknown
- 2016-08-19 US US15/753,353 patent/US10668077B2/en active Active
- 2016-08-19 FI FIEP16756763.5T patent/FI3337477T3/fi active
- 2016-08-19 HR HRP20230376TT patent/HRP20230376T1/hr unknown
- 2016-08-19 KR KR1020187007564A patent/KR20180064387A/ko not_active Withdrawn
- 2016-08-19 CN CN201680057437.6A patent/CN108348505B/zh active Active
- 2016-08-19 AU AU2016307885A patent/AU2016307885B2/en not_active Ceased
- 2016-08-19 LT LTEPPCT/GB2016/052575T patent/LT3337477T/lt unknown
- 2016-08-19 SM SM20230063T patent/SMT202300063T1/it unknown
- 2016-08-19 JP JP2018508757A patent/JP2018523689A/ja not_active Withdrawn
- 2016-08-19 EP EP16756763.5A patent/EP3337477B1/en active Active
- 2016-08-19 SI SI201631666T patent/SI3337477T1/sl unknown
- 2016-08-19 WO PCT/GB2016/052575 patent/WO2017029517A1/en not_active Ceased
- 2016-08-19 ES ES16756763T patent/ES2939815T3/es active Active
- 2016-08-19 HU HUE16756763A patent/HUE061615T2/hu unknown
-
2018
- 2018-02-13 IL IL257499A patent/IL257499A/en unknown
-
2020
- 2020-04-22 US US16/855,758 patent/US11291669B2/en active Active
-
2022
- 2022-03-01 US US17/684,020 patent/US12257254B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523689A5 (https=) | ||
| CN111886006B (zh) | 治疗肥大细胞增多症的组合疗法 | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| US9937174B2 (en) | Combinations of histone deacetylase inhibitors and bendamustine | |
| WO2021262484A1 (en) | Combination therapy for treatment of cancer | |
| US20160287605A1 (en) | Combination therapy | |
| ES3055488T3 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| JP2013528600A5 (https=) | ||
| JP2019515908A5 (https=) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| JPWO2022250170A5 (https=) | ||
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP5440985B2 (ja) | メラノーマの治療 | |
| JP2015522592A5 (https=) | ||
| US20150065526A1 (en) | Overcoming acquired resistance to chemotherapy treatments through suppression of stat3 | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| EP2538935B1 (en) | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine | |
| JP2016538295A5 (https=) | ||
| Kawahara et al. | Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas | |
| US20230060792A1 (en) | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy | |
| JP2019525924A5 (https=) | ||
| US9907797B2 (en) | Combination therapies for overcoming resistance to mitotic agents during chemotherapy | |
| RU2341260C2 (ru) | Комбинации, включающие производные эпотилона и алкилирующие агенты | |
| WO2025202854A1 (en) | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |